Chr. Hansen is supplier of probiotics to dietary supplements, infant formula and dairy, and through the acquisition of the LGG® business, the company is now further strengthening its microbial platform across all three categories.
Alongside Chr. Hansen’s own BB-12® strain, the Lactobacillus rhamnosus GG (protected under the trademark LGG®) is the best documented probiotic strain in the world. It has been used in food and dietary supplements since 1990 and has a proven beneficial effect on the gastrointestinal and immune system. It has been studied in more than 200 clinical studies and described in more than 800 scientific publications.
The price of the acquisition is EUR 73 million and will be funded through Chr. Hansen’s own cash position and existing credit facilities.